Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Telmisartan/Ramipril FDC vs Monocomponents
NCT02214979Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2007
- Primary completion
- Jun 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of telmisartan and ramipril in hypertension (HTN) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 96 hours and Maximum measured concentration up to 96 hours. Started Mar 2007; status: completed.
02
Drugs
telmisartanramipril
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02214979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02214979.